Publish in this journal
Journal Information
Vol. 17. Issue 5.
Pages 268-278 (May 2021)
Download PDF
More article options
Vol. 17. Issue 5.
Pages 268-278 (May 2021)
Original Article
DOI: 10.1016/j.reumae.2019.06.003
Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review
¿Es la obesidad un factor predictivo de falta de respuesta al tratamiento en la artritis psoriásica? Actualización de una revisión sistemática
Jordi Gratacósa, Eva Galíndezb, Teresa Otónc,
Corresponding author

Corresponding author.
a Servicio de Reumatología, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
b Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, Vizcaya, Spain
c Instituto de Salud Musculoesquelética, Madrid, Spain
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (2)
Table 1. Table of evidence. Description of included studies which analyse the association of obesity with response.
Table 2. Results from individual studies on the association between obesity and efficacy of psoriatic arthritis treatments.
Show moreShow less
Additional material (3)

To update the study of the association between obesity and treatment response in psoriatic arthritis.


Updating a systematic review of clinical trials, prospective or retrospective longitudinal studies and case–control studies in psoriatic arthritis in which obesity was assessed as a predictor of efficacy or toxicity. Risks of bias were assessed with validated scales. A meta-analysis of the results of studies with similar outcome variables and weight measurements was performed.


Twenty-one studies were included (6 review of clinical trials, 6 longitudinal studies, 7 registers and one case–control studie), with moderate quality. The risk of achieving an ACR20 response if weight100kg was estimated at OR=1.42 (1–2.08) and that of withdrawing treatment in an OR of 1.60 (95% CI: 1.34–1.92).


There seems to be a greater risk of withdrawal of treatment due to inefficacy and difficulty in achieving remission in patients with psoriatic arthritis if they are obese.

Psoriatic arthritis
Therapeutic response
Predictive factors
Systematic review

Actualizar el estudio de la asociación entre obesidad y respuesta al tratamiento en artritis psoriásica.


Actualización de una revisión sistemática previa, incluyendo ensayos clínicos aleatorizados, estudios longitudinales y casos-control en artritis psoriásica en los que se evaluase obesidad como predictor de eficacia o toxicidad. Los riesgos de sesgos se evaluaron con escalas validadas. Se realizó metaanálisis de los resultados de estudios con variables de desenlace y medidas del peso similares.


Se incluyeron 21 estudios (6 ensayos clínicos aleatorizados, 6 estudios longitudinales, 7 registros y un caso-control), de calidad en general moderada. El riesgo de no respuesta ACR20 si el peso es100kg se estimó en OR=1.42 (1-2.08) y el de retirar el tratamiento en una OR de 1.60 (IC 95%: 1.34-1.92).


Parece existir un mayor riesgo de retirada del tratamiento por ineficacia y dificultad para conseguir remisión en pacientes con artritis psoriásica si son obesos.

Palabras clave:
Artritis psoriásica
Respuesta terapéutica
Factores predictivos
Revisión sistemática


These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Reumatología Clínica (English Edition)

Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?